Summary
Johnson & Johnson (JNJ) announced a change in its sales reporting format, effective for the first quarter of 2012. This initiative aims to provide investors with greater clarity and better alignment of reported sales with the company's operational structure. The new format will enhance the granularity of reporting within the Pharmaceutical and Medical Devices and Diagnostics segments, offering insights into key therapeutic areas and product categories.
Key Highlights
- 1JNJ is implementing a new sales reporting format starting Q1 2012 for enhanced clarity and operational alignment.
- 2The Pharmaceutical segment will now report sales by specific therapeutic areas (Immunology, Infectious Diseases, Neuroscience, Oncology) and key products within them.
- 3The Medical Devices and Diagnostics segment has undergone significant restructuring in its sales reporting categories, with some areas renamed or consolidated.
- 4Key changes in Medical Devices and Diagnostics include renaming 'Diagnostics' to 'Orthopa-Clinical Diagnostics', consolidating various Ethicon and Ethicon Endo-Surgery businesses into 'General Surgery', 'Infection Prevention/Other', and 'Specialty Surgery', and renaming 'DePuy' to 'Orthopaedics'.
- 5Sales reporting for the Consumer segment remains unchanged.
- 6The filing includes updated 2011 sales schedules reflecting the new format, available on JNJ's investor website and the SEC's EDGAR database.
- 7The report contains standard forward-looking statements outlining potential risks and uncertainties that could affect future results.
Frequently Asked Questions
Johnson & Johnson is changing its sales reporting format to provide investors with greater clarity and better alignment of reported sales with its operational structure. This allows for more detailed insights into performance across key therapeutic areas and product categories.
In the Pharmaceutical segment, JNJ will now report sales by specific therapeutic areas, including Immunology, Infectious Diseases, Neuroscience, and Oncology. It will also report sales of key products within these therapeutic areas, offering a more granular view of performance.
The Medical Devices and Diagnostics segment has seen several changes. 'Diagnostics' is now 'Orthopa-Clinical Diagnostics'. Several businesses previously under Ethicon and Ethicon Endo-Surgery have been consolidated into categories like 'General Surgery', 'Infection Prevention/Other', and 'Specialty Surgery'. 'DePuy' has been renamed 'Orthopaedics'.
The updated sales schedules reflecting the new format for 2011 are attached as an exhibit. This information, along with future reports, will be available on Johnson & Johnson's investor relations website (www.investor.jnj.com) and the SEC's EDGAR database (www.sec.gov).